YZR Capital Research
Investment Thesis
YZR Capital is a founder-led, independent healthcare investment platform based in Munich, Germany. The firm describes its mission as backing ambitious entrepreneurs who tackle complex challenges in global healthcare, and it says it supports portfolio companies with functional and healthcare-specific know-how from day one. It wants to help build global champions with lasting impact. Its stated focus is Europe's HealthTech pioneers: tech-enabled companies that improve patient care, increase provider efficiency, or innovate healthcare value chains. The website sorts the portfolio into exactly those three buckets. YZR was founded in 2021 and says it launched to fill a knowledge gap in European health tech and to deploy capital when other investors paused. The name is pronounced 'waizer' and blends 'wise' with the river Isar, a nod to its Munich roots.
Stage Focus
The About page says YZR partners with founders from (pre-)Seed to Series B. Third-party profiles (Private Equity International, Superscout) describe the core as pre-seed, seed and Series A. The portfolio shows a mix of early rounds and companies that have since raised large later rounds, such as Scan.com and Biorce.
Check Size
No check size is published. Superscout says check sizes vary by stage and run from pre-seed to growth equity. This is not verified and is left out of the structured fields.
Lead Tendency
The site does not say whether YZR leads or follows. Lead tendency is recorded as unknown.
Fund and Recent Activity
The careers page and third-party profiles describe a current fund of about EUR 100 million focused on early-stage health tech in Europe, backed by what the site calls top-tier LPs. The fund appears to be actively deploying. The latest portfolio news on the firm's own Spotlight page:
- September 2026: Scan.com raised $220 million to scale medical imaging infrastructure.
- April to May 2026: dehaze raised EUR 3.2 million for AI chronic disease detection.
- February 2026: Biorce raised a reported $52 million (EUR 44.6 million) Series A for AI-driven clinical trials.
- January 2026: Scan.com ranked second among healthtech startups in the Sunday Times 100 Tech.
- November 2025: Sifted 250 listed Scan.com in the top 10 of HealthTech; roclub raised $11.7 million.
Portfolio Highlights
The portfolio page lists 12 companies across Austria, Germany, France, Spain, Poland, the UK and other European markets:
- dehaze: AI platform for chronic disease detection
- Roclub: teleoperation platform for MedTech
- Doctor.One: identification of chronic care paths
- Scan.com: medical imaging marketplace
- Biorce: faster and smarter drug development
- Filu: tech-enabled veterinary clinic chain
- Deepeye Medical: treatment support for retinal diseases
- Deeplife: therapy discovery and drug development
- OpenHealth Technologies: lab data harmonization platform
- DaphOS: AI-driven resource management in healthcare
- Ima Health: medication-as-a-service for polypharmacy patients
- apoQlar: mixed reality for healthcare
The site states Scan.com and Biorce as its standout performers, and claims a biggest valuation uplift of more than a given multiple (the figure is animated and not readable in the page text).
Team
- Prof. Dr. Reinhard Meier, Co-Founder and Managing Partner: former practising physician and Professor of Radiology; co-founded telemedicine platform TeleClinic.com, sold to a public company in 2020; invests health tech through his family office.
- Markus Feuerecker, Co-Founder and Managing Partner: VC, growth and buyout PE investor; formerly Vice President at DPE Deutsche Private Equity and Senior Investment Manager at EMERAM Capital Partners.
- Christina Schmidt, Investor: over five years in VC, previously ALSTIN Capital and Vito Ventures, and business development at Holidu.
- Till Quitzau, Investor: former Associate Consultant at Bain and Company; VC internship at Redalpine; ESADE and Mannheim.
- Georg Grudow Alonso, Investor: ex-investment banking at GP Bullhound.
- Venture Partners: Urs Keller, Holger Ebersberger, Dr. Martina Samwer.
- Senior Advisors: Dr. med. Michael Bitzer and Elmar H. Willebrand.
Decision Process
Not published. The firm calls itself founder-led and says it moves fast. The two managing partners are co-founders, so a partnership model is the most likely structure, but it is not confirmed.
Founder Preferences
The firm favors teams solving large healthcare problems with scalable, tech-enabled solutions, and stresses strong personal relationships, shared ambition and the freedom to innovate. It highlights its own mix of medical insight, operator experience and investor firepower. Founders can pitch through a form on the site.
Geographic Focus
Europe, with the portfolio anchored in the DACH region, Spain, Poland, France and the UK. The site has a filter listing Austria, France, Germany, Netherlands, Poland, Portugal, Spain, Sweden, Ukraine, the UK and the USA.
Gaps
Check size, lead tendency, decision timeline and investment dates are not published. Portfolio stage at investment is not stated for any company, so none is recorded.